drugset / Trial / NCT04375735
London's Exogenous Surfactant Study for COVID19
Phase 1/2
Completed
20 enrolled
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
London Health Sciences Centre · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
The research team is investigating administering exogenous surfactant in COVID-19 patients with ARDS. The overall goal is to improve the outcome (mortality) of mechanically ventilated COVID-19 patients. Although the investigators anticipate that clinical outcomes may improve in the small group of patients receiving exogenous surfactant therapy in this small, single center study, the primary goal is to first determine feasibility and safety.
Timeline
- Start
- 2020-11-23
- Primary completion
- 2021-09-01
- Completion
- 2021-10-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bovine Lipid Extract Surfactant | Unknown | 50 mg/kg | Other |